gamma-aminobutyric acid has been researched along with Dyskinesia, Medication-Induced in 142 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have observed two cases of chlorpromazine-induced neuroleptic malignant syndrome (NMS); both were transiently responsive to intravenous diazepam challenge, but not to blind placebo or amyobarbitol." | 9.05 | Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. ( Lew, TY; Tollefson, G, 1983) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 7.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| " I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride." | 7.68 | Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990) |
| "We have observed two cases of chlorpromazine-induced neuroleptic malignant syndrome (NMS); both were transiently responsive to intravenous diazepam challenge, but not to blind placebo or amyobarbitol." | 5.05 | Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. ( Lew, TY; Tollefson, G, 1983) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 3.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| " We present a case of asterixis as a cause of falls and near falls in a patient with metastatic breast cancer and normal mental status who was receiving gabapentin." | 3.73 | Asterixis related to gabapentin as a cause of falls. ( Babiy, M; Hand, M; Herklotz, M; Stubblefield, MD, 2005) |
| "We report two cases of unusual movement disorders associated with the use of gabapentin (GBP) in patients being treated for epilepsy who were otherwise neurologically intact." | 3.69 | Movement disorders associated with the use of gabapentin. ( Krahn, LE; Reeves, AL; Sharbrough, FW; So, EL, 1996) |
| " I report a patient who developed the syndrome during treatment for schizophrenia with the antipsychotic agent molindone hydrochloride." | 3.68 | Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen. ( Sandyk, R, 1990) |
| "We measured the contents of gamma-aminobutyric acid (GABA) and of other amino compounds in five regions of autopsied brain from 18 patients with schizophrenia and from a large group of adult control subjects dying without any neurological or psychiatric disorder." | 3.67 | Schizophrenia, tardive dyskinesia, and brain GABA. ( Hansen, S; Jones, K; Perry, TL, 1989) |
| " Tolerance developed to the antidyskinetic effect of clonazepam in the five patients whose long-term use of the drug was followed, but a 2-week clonazepam-free period recaptured its antidyskinetic effect." | 2.67 | Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. ( Jacobson, R; Kaup, BA; Nguyen, JA; Strauss, ME; Tamminga, CA; Thaker, GK, 1990) |
| "Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias." | 2.44 | Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. ( Encarnacion, EV; Hauser, RA, 2008) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "The dichotomy of Parkinson's disease; akinesia with increased tone, and the mirror effects in Huntington's disease; hemiballismus and tardive dyskinesia, hyperkinesia with decreased tone are explained as due to two outputs of the system with an intervening inhibitory neuron which reverses the sign." | 2.36 | The basal ganglia in extrapyramidal dysfunction. ( Barnes, CD, 1983) |
| " Chronic administration of haloperidol (1 mg/kg, i." | 1.35 | Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. ( Bishnoi, M; Chopra, K; Kulkarni, SK, 2008) |
| "Treatment with baclofen (4 mg/kg) did not modify spontaneous VCM." | 1.33 | Effects of baclofen on reserpine-induced vacuous chewing movements in mice. ( Abílio, VC; Castro, JP; Frussa-Filho, R; Fukushiro, DF; Medrano, WA; Ribeiro, Rde A; Silva, RH, 2006) |
| " On day 10, the locomotor response to L-dopa was significantly potentiated by chronic administration of idazoxan." | 1.31 | Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. ( Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P, 2000) |
| "Treatment of Parkinson's disease with L-dopa is plagued in a majority of patients by dyskinesias." | 1.31 | Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. ( Bédard, PJ; Doan, VD; Grondin, R; Hadj Tahar, A; Ladure, P, 2000) |
| "Acute and chronic administration of vigabatrin, a selective inactivator of GABA-T, suppresses haloperidol-induced dyskinesias at low doses without preventing the enhancement of striatal dopamine D2 receptor density or the development of vacuous chewing movements." | 1.29 | Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. ( Elands, J; Gobaille, S; Grauffel, C; Knödgen, B; Moran, P; Sarhan, S; Seiler, N; van den Buuse, M, 1995) |
| "Chronic administration of haloperidol to male Sprague Dawley rats for 6 months at a dosage of 1." | 1.29 | Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. ( Friedman, MB; Gao, XM; Kakigi, T; Tamminga, CA, 1994) |
| " This phenomenon, probably due to the inhibition of the striato-nigral GABA-ergic pathway, could serve as an easy and reliable model for the human tardive dyskinesias dues to the chronic administration of neuroleptics." | 1.28 | [Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man]. ( Vamvakides, A, 1989) |
| "In ongoing studies of chronic administration of neuroleptics to monkeys (Cebus apella) and rats, the regional distribution of glutamic acid decarboxylase (GAD) and brain levels of homovanillic acid were examined." | 1.27 | Experimental tardive dyskinesia. ( Gunne, LM; Häggström, JE, 1985) |
| "Tetrahydroisoxazolopyridinol (THIP), a GABA receptor agonist, gamma-acetylenic-GABA(GAG) and gamma-vinyl-GABA(GVG), two GABA transaminase inhibitors were given in single parenteral doses to three Cebus apella monkeys with persistent dyskinetic movements induced by earlier long-term administration of haloperidol." | 1.27 | GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias. ( Andersson, U; Häggström, JE, 1988) |
| " While numerous reports of the partial effectiveness of acute treatment with cholinergic or GABAergic agents have appeared, the effects of chronic administration of these substance are unclear." | 1.26 | Symptomatic treatment of tardive dyskinesia: a word of caution. ( Kucharski, LT; Unterwald, EM, 1981) |
| "Muscimol, thought to be a agonist of gamma-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia." | 1.26 | Improvement in tardive dyskinesia after muscimol therapy. ( Chase, TN; Crayton, JW; Tamminga, CA, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (56.34) | 18.7374 |
| 1990's | 15 (10.56) | 18.2507 |
| 2000's | 32 (22.54) | 29.6817 |
| 2010's | 10 (7.04) | 24.3611 |
| 2020's | 5 (3.52) | 2.80 |
| Authors | Studies |
|---|---|
| Nudelman, A | 1 |
| Gil-Ad, I | 1 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 1 |
| Geffen, Y | 1 |
| Weizman, A | 1 |
| Rephaeli, A | 1 |
| Avila-Luna, A | 1 |
| Gálvez-Rosas, A | 1 |
| Aguirre-Pérez, A | 1 |
| Hidalgo-Bravo, A | 1 |
| Alfaro-Rodriguez, A | 1 |
| Ríos, C | 1 |
| Arias-Montaño, JA | 1 |
| Bueno-Nava, A | 1 |
| Abe, Y | 1 |
| Yagishita, S | 1 |
| Sano, H | 1 |
| Sugiura, Y | 1 |
| Dantsuji, M | 1 |
| Suzuki, T | 1 |
| Mochizuki, A | 1 |
| Yoshimaru, D | 1 |
| Hata, J | 1 |
| Matsumoto, M | 1 |
| Taira, S | 1 |
| Takeuchi, H | 1 |
| Okano, H | 1 |
| Ohno, N | 1 |
| Suematsu, M | 1 |
| Inoue, T | 1 |
| Nambu, A | 1 |
| Watanabe, M | 1 |
| Tanaka, KF | 1 |
| Kiessling, CY | 1 |
| Lanza, K | 1 |
| Feinberg, E | 1 |
| Bishop, C | 1 |
| Nishijima, H | 1 |
| Mori, F | 1 |
| Arai, A | 1 |
| Zhu, G | 1 |
| Wakabayashi, K | 1 |
| Okada, M | 1 |
| Ueno, S | 1 |
| Ichinohe, N | 1 |
| Suzuki, C | 1 |
| Kon, T | 1 |
| Tomiyama, M | 1 |
| Brugnoli, A | 2 |
| Pisanò, CA | 1 |
| Morari, M | 9 |
| Alabed, S | 1 |
| Latifeh, Y | 1 |
| Mohammad, HA | 1 |
| Bergman, H | 1 |
| Mabrouk, OS | 2 |
| Mela, F | 3 |
| Calcagno, M | 1 |
| Budri, M | 1 |
| Viaro, R | 1 |
| Dekundy, A | 2 |
| Parsons, CG | 1 |
| Auberson, YP | 1 |
| Paolone, G | 1 |
| Arcuri, L | 1 |
| Mercatelli, D | 1 |
| McCreary, AC | 1 |
| Varney, MA | 1 |
| Newman-Tancredi, A | 1 |
| Solís, O | 1 |
| García-Sanz, P | 1 |
| Herranz, AS | 1 |
| Asensio, MJ | 1 |
| Moratalla, R | 1 |
| Varty, GB | 1 |
| Hodgson, RA | 1 |
| Pond, AJ | 1 |
| Grzelak, ME | 1 |
| Parker, EM | 1 |
| Hunter, JC | 1 |
| Marti, M | 6 |
| Trapella, C | 1 |
| Rangel-Barajas, C | 1 |
| Silva, I | 1 |
| Lopéz-Santiago, LM | 1 |
| Aceves, J | 1 |
| Erlij, D | 1 |
| Florán, B | 1 |
| Bido, S | 2 |
| Cenci, MA | 2 |
| Rodi, D | 1 |
| Li, Q | 1 |
| Guerrini, R | 1 |
| Fasano, S | 1 |
| Morella, I | 1 |
| Tozzi, A | 1 |
| Brambilla, R | 1 |
| Calabresi, P | 1 |
| Simonato, M | 1 |
| Bezard, E | 1 |
| Fox, SH | 3 |
| Henry, B | 1 |
| Hill, M | 3 |
| Crossman, A | 1 |
| Brotchie, J | 1 |
| Hardoy, MC | 2 |
| Carta, MG | 2 |
| Carpiniello, B | 1 |
| Cianchetti, C | 1 |
| Congia, S | 1 |
| D'Errico, I | 1 |
| Emanuelli, G | 1 |
| Garonna, F | 1 |
| Hardoy, MJ | 2 |
| Nardini, M | 1 |
| Kase, H | 1 |
| Aoyama, S | 1 |
| Ichimura, M | 1 |
| Ikeda, K | 1 |
| Ishii, A | 1 |
| Kanda, T | 1 |
| Koga, K | 1 |
| Koike, N | 1 |
| Kurokawa, M | 1 |
| Kuwana, Y | 1 |
| Mori, A | 1 |
| Nakamura, J | 1 |
| Nonaka, H | 1 |
| Ochi, M | 1 |
| Saki, M | 1 |
| Shimada, J | 1 |
| Shindou, T | 1 |
| Shiozaki, S | 1 |
| Suzuki, F | 1 |
| Takeda, M | 1 |
| Yanagawa, K | 1 |
| Richardson, PJ | 1 |
| Jenner, P | 1 |
| Bedard, P | 1 |
| Borrelli, E | 1 |
| Hauser, RA | 2 |
| Chase, TN | 4 |
| Sechi, G | 1 |
| Murgia, B | 1 |
| Sau, G | 1 |
| Peddone, L | 1 |
| Tirotto, A | 1 |
| Barrocu, M | 1 |
| Rosati, G | 1 |
| Ishiwari, K | 1 |
| Mingote, S | 1 |
| Correa, M | 1 |
| Trevitt, JT | 1 |
| Carlson, BB | 1 |
| Salamone, JD | 1 |
| Babiy, M | 1 |
| Stubblefield, MD | 1 |
| Herklotz, M | 1 |
| Hand, M | 1 |
| van der Stelt, M | 1 |
| Crossman, AR | 2 |
| Petrosino, S | 1 |
| Di Marzo, V | 1 |
| Brotchie, JM | 2 |
| Horvath, J | 1 |
| Coeytaux, A | 1 |
| Jallon, P | 1 |
| Landis, T | 1 |
| Temperli, P | 1 |
| Burkhard, PR | 1 |
| Heckmann, JG | 1 |
| Ulrich, K | 1 |
| Dütsch, M | 1 |
| Neundörfer, B | 1 |
| Castro, JP | 1 |
| Frussa-Filho, R | 1 |
| Fukushiro, DF | 1 |
| Silva, RH | 1 |
| Medrano, WA | 1 |
| Ribeiro, Rde A | 1 |
| Abílio, VC | 1 |
| Deogaonkar, A | 1 |
| Deogaonkar, M | 1 |
| Lee, JY | 1 |
| Ebrahim, Z | 1 |
| Schubert, A | 1 |
| Raju, PM | 1 |
| Walker, RW | 1 |
| Lee, MA | 1 |
| Danysz, W | 1 |
| Bishnoi, M | 1 |
| Chopra, K | 1 |
| Kulkarni, SK | 4 |
| Carta, AR | 1 |
| Frau, L | 1 |
| Lucia, F | 1 |
| Pinna, A | 1 |
| Annalisa, P | 1 |
| Pontis, S | 1 |
| Silvia, P | 1 |
| Simola, N | 1 |
| Nicola, S | 1 |
| Schintu, N | 1 |
| Nicoletta, S | 1 |
| Morelli, M | 1 |
| Micaela, M | 1 |
| Encarnacion, EV | 1 |
| Berger, PA | 3 |
| Rexroth, K | 1 |
| Barbaccia, ML | 1 |
| Trabucchi, M | 1 |
| Casey, DE | 4 |
| Gerlach, J | 5 |
| Magelund, G | 2 |
| Christensen, TR | 2 |
| Logothetis, J | 1 |
| Paraschos, A | 1 |
| Frangos, E | 1 |
| Hollister, LE | 1 |
| Lloyd, KG | 3 |
| Worms, P | 1 |
| Wray, SR | 1 |
| Melville, GN | 1 |
| Grell, GA | 1 |
| Edge, PC | 1 |
| Gale, K | 2 |
| Casu, M | 1 |
| Ananth, J | 1 |
| Alphs, L | 1 |
| Davis, JM | 1 |
| Tanner, CM | 1 |
| Tamminga, CA | 12 |
| Thaker, GK | 8 |
| Ferraro, TN | 2 |
| Hare, TA | 3 |
| Meldrum, B | 1 |
| Barnes, CD | 1 |
| Hammond, EJ | 3 |
| Wilder, BJ | 3 |
| Bruni, J | 1 |
| Bartholini, G | 2 |
| Neale, R | 1 |
| Gerhardt, S | 1 |
| Liebman, JM | 1 |
| Wesemann, W | 1 |
| Sontag, KH | 1 |
| Maj, J | 1 |
| Bjørndal, N | 1 |
| Christensson, E | 1 |
| Robin, MM | 2 |
| Palfreyman, MG | 2 |
| Zraika, MM | 1 |
| Schechter, PJ | 2 |
| Marsden, CD | 1 |
| Sheehy, MP | 1 |
| Rastogi, SK | 2 |
| Rastogi, RB | 2 |
| Singhal, RL | 2 |
| Lapierre, YD | 2 |
| Lew, TY | 1 |
| Tollefson, G | 1 |
| Kucharski, LT | 1 |
| Unterwald, EM | 1 |
| Cutler, NR | 1 |
| Post, RM | 1 |
| Robin, M | 1 |
| Palfreyman, M | 1 |
| Zraika, M | 1 |
| Schechter, P | 1 |
| Crews, EL | 1 |
| Seiler, N | 1 |
| Grauffel, C | 1 |
| Elands, J | 1 |
| van den Buuse, M | 1 |
| Knödgen, B | 1 |
| Sarhan, S | 1 |
| Moran, P | 1 |
| Gobaille, S | 1 |
| Gao, XM | 1 |
| Kakigi, T | 1 |
| Friedman, MB | 1 |
| Gunne, LM | 7 |
| Andrén, PE | 2 |
| Shirakawa, O | 2 |
| Maeda, K | 1 |
| Sakai, K | 1 |
| Spooren, WP | 1 |
| Mulders, WH | 1 |
| Veening, JG | 1 |
| Cools, AR | 2 |
| Buetefisch, CM | 1 |
| Gutierrez, A | 1 |
| Gutmann, L | 1 |
| Reeves, AL | 1 |
| So, EL | 1 |
| Sharbrough, FW | 1 |
| Krahn, LE | 1 |
| Cabras, PL | 1 |
| Grondin, R | 1 |
| Hadj Tahar, A | 1 |
| Doan, VD | 1 |
| Ladure, P | 1 |
| Bédard, PJ | 1 |
| Sachdev, PS | 1 |
| Grimm, JW | 1 |
| See, RE | 2 |
| Tanii, H | 1 |
| Zang, X | 1 |
| Saito, N | 1 |
| Saijoh, K | 1 |
| Naidu, PS | 3 |
| Raghavendra, V | 1 |
| Ghaemi, SN | 1 |
| Ko, JY | 1 |
| Berglind, WJ | 1 |
| Sieradzan, KA | 1 |
| Dick, JP | 1 |
| Norton, JW | 1 |
| Quarles, E | 1 |
| Lastres-Becker, I | 1 |
| Hansen, HH | 1 |
| Berrendero, F | 1 |
| De Miguel, R | 1 |
| Pérez-Rosado, A | 1 |
| Manzanares, J | 1 |
| Ramos, JA | 1 |
| Fernández-Ruiz, J | 1 |
| Chien, C | 1 |
| Jung, K | 1 |
| Ross-Townsend, A | 1 |
| Crayton, JW | 1 |
| Costentin, J | 1 |
| Mackay, AV | 1 |
| Sheppard, GP | 1 |
| Faull, KF | 1 |
| DoAmaral, JR | 1 |
| Barchas, JD | 1 |
| Makeeva, VL | 1 |
| Scarnati, E | 1 |
| Forchetti, C | 1 |
| Ruggieri, S | 1 |
| Agnoli, A | 1 |
| Standefer, MJ | 1 |
| Dill, RE | 1 |
| Cassady, SL | 1 |
| Moran, M | 1 |
| Birt, A | 1 |
| Kaneda, H | 1 |
| Dale, J | 1 |
| Goodman, L | 1 |
| Bachus, SE | 2 |
| Grant, SM | 1 |
| Heel, RC | 1 |
| Nguyen, JA | 3 |
| Strauss, ME | 1 |
| Jacobson, R | 1 |
| Kaup, BA | 1 |
| Sandyk, R | 2 |
| Ciu, Z | 1 |
| Gao, BL | 1 |
| Häggström, JE | 4 |
| Johansson, P | 1 |
| Levin, ED | 1 |
| Terenius, L | 1 |
| Spooren, W | 1 |
| Bezemer, R | 1 |
| Cuypers, E | 1 |
| Jaspers, R | 1 |
| Groenewegen, H | 1 |
| Perry, TL | 1 |
| Hansen, S | 1 |
| Jones, K | 1 |
| Vamvakides, A | 4 |
| Ungerstedt, U | 1 |
| Herrera-Marschitz, M | 1 |
| Forster, C | 1 |
| Arushanian, EB | 1 |
| Cross, AJ | 1 |
| Crow, TJ | 1 |
| Ferrier, IN | 1 |
| Johnson, JA | 1 |
| Johnstone, EC | 1 |
| Owen, F | 1 |
| Owens, DG | 1 |
| Poulter, M | 1 |
| Morselli, PL | 2 |
| Fournier, V | 2 |
| Bossi, L | 1 |
| Musch, B | 1 |
| Kashihara, K | 1 |
| Ebara, T | 1 |
| Yamamoto, M | 1 |
| Ogawa, T | 1 |
| Harada, T | 1 |
| Otsuki, S | 1 |
| Perrault, G | 1 |
| Zivkovic, B | 1 |
| Rondot, P | 3 |
| Bathien, N | 2 |
| Mithani, S | 1 |
| Atmadja, S | 1 |
| Baimbridge, KG | 1 |
| Fibiger, HC | 1 |
| Andersson, U | 1 |
| Ziegler, M | 1 |
| Scheel-Krüger, J | 1 |
| Arnt, J | 1 |
| Alphs, LD | 1 |
| Lafferman, J | 1 |
| Jeste, DV | 1 |
| Lohr, JB | 1 |
| Clark, K | 1 |
| Wyatt, RJ | 1 |
| Toth, E | 1 |
| Lajtha, A | 1 |
| Gaio, JM | 1 |
| Pollak, P | 1 |
| Hommel, M | 1 |
| Perret, J | 1 |
| Stahl, SM | 1 |
| Thornton, JE | 1 |
| Simpson, ML | 1 |
| Napoliello, MJ | 1 |
| Mukherjee, S | 1 |
| Wisniewski, A | 1 |
| Bilder, R | 1 |
| Sackeim, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease[NCT03639064] | Phase 2 | 15 participants (Anticipated) | Interventional | 2020-12-01 | Recruiting | ||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
30 reviews available for gamma-aminobutyric acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.
Topics: Antipsychotic Agents; Baclofen; Dyskinesia, Drug-Induced; GABA Agonists; gamma-Aminobutyric Acid; Hu | 2018 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus S | 2003 |
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Topics: Aged; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Deep Brain Stimulation; Dopamin | 2008 |
Tardive dyskinesia: a biological appraoch.
Topics: Animals; Antipsychotic Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Human | 1980 |
Neuropharmacological actions of GABA agonists: predictability for their clinical usefulness.
Topics: Antipsychotic Agents; Brain Chemistry; Dyskinesia, Drug-Induced; Epilepsy; gamma-Aminobutyric Acid; | 1981 |
Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder.
Topics: Amphetamine; Animals; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Avoidance | 1981 |
Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
Topics: 4-Aminobutyrate Transaminase; Afferent Pathways; Aminocaproates; Animals; Basal Ganglia; Behavior, A | 1981 |
Current psychopathological theories of tardive dyskinesia and their implications for future research.
Topics: Acetylcholine; Adult; Aged; Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced | 1982 |
Treatment of tardive dyskinesia: other therapies.
Topics: Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Neurotransmitter Agents; Norepi | 1983 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
The basal ganglia in extrapyramidal dysfunction.
Topics: Basal Ganglia; Basal Ganglia Diseases; Corpus Striatum; Dyskinesia, Drug-Induced; Feedback; gamma-Am | 1983 |
Central actions of valproic acid in man and in experimental models of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Action Potentials; Alcohol Oxidoreductases; Aldehyde Oxidoreductases; | 1981 |
GABA system, GABA receptor agonists and dyskinesia.
Topics: Basal Ganglia; Cholinergic Fibers; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Huma | 1983 |
[Pharmacodynamics and pharmacokinetics of memantine].
Topics: Amantadine; Animals; Antidepressive Agents; Body Temperature; Catalepsy; Dopamine; Dyskinesia, Drug- | 1983 |
GABA system: clinical research and treatment of tardive dyskinesia.
Topics: Alkynes; Aminocaproates; Benzodiazepines; Clinical Trials as Topic; Corpus Striatum; Dopamine; Dyski | 1983 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; | 2000 |
The current status of tardive dyskinesia.
Topics: Age Factors; Antipsychotic Agents; Cholinergic Antagonists; Dyskinesia, Drug-Induced; Free Radicals; | 2000 |
Neurotransmitter interactions related to central dopamine neurons.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopam | 1978 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria | 1979 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
[Significance of GABA-energic system in the central nervous system in clinical psychologic medicine].
Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hepatic Encephalopathy; | 1990 |
Neurobiochemical changes in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Cebus; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid | 1988 |
GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism.
Topics: Animals; Brain Chemistry; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans | 1989 |
[Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
Topics: Animals; Antipsychotic Agents; Cats; Cholinergic Fibers; Corpus Striatum; Dopamine; Dyskinesia, Drug | 1985 |
[Implications of GABAergic synapses in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; | 1985 |
[Tardive dyskinesias. Epidemiology and physiopathology].
Topics: Adult; Aged; Antipsychotic Agents; Denmark; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Aci | 1987 |
Gamma-vinyl GABA.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Behavior, Animal; beta-Alanine; | 1985 |
Pharmacological treatments of tardive dyskinesia in the 1980s.
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Norepinephrine; Parasympatholytics; Paras | 1988 |
[Effect of glycine-steatamide or glutamic acid palmitamide on oral dyskinesia, obtained by a single administration of haloperidol combined with GABA-linoleamide in rats].
Topics: Animals; Drug Combinations; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Glutamates; G | 1988 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
17 trials available for gamma-aminobutyric acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Dyskine | 2003 |
gamma-Acetylenic GABA in tardive dyskinesia.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Alkynes; Aminocaproates; Antipsychotic Agents; Brain; Dop | 1980 |
GABA agonist treatment improves tardive dyskinesia.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Clinical Trials as Topic; Double-Blind Method; Dyskine | 1983 |
GABA system: clinical research and treatment of tardive dyskinesia.
Topics: Alkynes; Aminocaproates; Benzodiazepines; Clinical Trials as Topic; Corpus Striatum; Dopamine; Dyski | 1983 |
GABA and movement disorders.
Topics: Anticonvulsants; Baclofen; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; | 1981 |
Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.
Topics: Brain; Chlorpromazine; Diazepam; Dopamine; Dyskinesia, Drug-Induced; Dystonia; Female; Fever; gamma- | 1983 |
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Topics: Aged; Animals; Cross-Over Studies; Culture Techniques; Double-Blind Method; Dronabinol; Dyskinesia, | 2001 |
Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia [proceedings].
Topics: Acetylcholine; Clinical Trials as Topic; Deanol; Dopamine; Dyskinesia, Drug-Induced; Ethanolamines; | 1978 |
Pharmacotherapeutic trials in tardive dyskinesia.
Topics: Acetylcholine; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Administrat | 1979 |
GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induc | 1992 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.
Topics: Adult; Antipsychotic Agents; Athetosis; Chorea; Clonazepam; Double-Blind Method; Dyskinesia, Drug-In | 1990 |
Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Metho | 1985 |
Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Corpus Striatum; Double-Blind Method; Dyskinesia, Dr | 1987 |
Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-I | 1987 |
Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
Topics: Adult; Aminocaproates; Brain; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induce | 1987 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
98 other studies available for gamma-aminobutyric acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
Chronic H
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 2023 |
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobut | 2023 |
Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2020 |
GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; L | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; | 2020 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 2013 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; | 2015 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relati | 2016 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; | 2016 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2008 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2010 |
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Le | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyski | 2011 |
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Topics: Animals; Benzazepines; Corpus Striatum; Dopamine Antagonists; Dyskinesia, Drug-Induced; gamma-Aminob | 2012 |
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia | 2012 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix | 2002 |
Asterixis and toxic encephalopathy induced by gabapentin.
Topics: Acetates; Aged; Amines; Anticonvulsants; Brain; Brain Diseases; Carbamazepine; Cyclohexanecarboxylic | 2004 |
The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis.
Topics: Animals; beta-Alanine; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response R | 2004 |
Asterixis related to gabapentin as a cause of falls.
Topics: Accidental Falls; Aged; Amines; Analgesics; Breast Neoplasms; Cyclohexanecarboxylic Acids; Diagnosis | 2005 |
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
Topics: Animals; Arachidonic Acids; Callithrix; Cannabinoid Receptor Modulators; Dyskinesia, Drug-Induced; E | 2005 |
Carbamazepine encephalopathy masquerading as Creutzfeldt-Jakob disease.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Atrophy; Basal Ganglia; Brain; Brain Damage, Chronic; Carbam | 2005 |
Pregabalin associated asterixis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Analgesics; Dyskinesia, Drug-Induced; Female; gamma-Amino | 2005 |
Effects of baclofen on reserpine-induced vacuous chewing movements in mice.
Topics: Adrenergic Uptake Inhibitors; Animals; Baclofen; Brain; Brain Chemistry; Dose-Response Relationship, | 2006 |
Propofol-induced dyskinesias controlled with dexmedetomidine during deep brain stimulation surgery.
Topics: Deep Brain Stimulation; Dexmedetomidine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; | 2006 |
Dyskinesia induced by gabapentin in idiopathic Parkinson's disease.
Topics: Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Dyskinesia, Drug-Induced; Gabapenti | 2007 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-In | 2007 |
Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Topics: Animals; Antipsychotic Agents; Brain Diseases; Control Groups; Disease Models, Animal; Dopamine; Dys | 2008 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St | 2008 |
Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Choline; Corpus Striatum; Diagnosis, Differential; Dop | 1980 |
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.
Topics: Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Pa | 1981 |
Treatment of tardive dyskinesia.
Topics: Antipsychotic Agents; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans | 1980 |
Noncatecholaminergic treatments of tardive dyskinesia.
Topics: Amantadine; Anti-Anxiety Agents; Benzodiazepines; Cyproheptadine; D-Ala(2),MePhe(4),Met(0)-ol-enkeph | 1982 |
Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Avoidance Learning; Catecholamines; Dyskinesia, Drug-I | 1984 |
Methylphenidate, apomorphine, THIP, and diazepam in monkeys: dopamine-GABA behavior related to psychoses and tardive dyskinesia.
Topics: Animals; Apomorphine; Chlorocebus aethiops; Diazepam; Dopamine; Drug Interactions; Dyskinesia, Drug- | 1984 |
An analysis of the cortical and striatal involvement in dyskinesia induced in rats by intracerebral injection of GABA-transaminase inhibitors and picrotoxin.
Topics: 4-Aminobutyrate Transaminase; Administration, Topical; Animals; Brain; Cerebral Cortex; Corpus Stria | 1980 |
SL76002 - effect on gamma-aminobutyric acid and dopamine in animals treated chronically with haloperidol.
Topics: Animals; Brain Chemistry; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Frontal Lobe; gamma-A | 1983 |
Symptomatic treatment of tardive dyskinesia: a word of caution.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Mus | 1981 |
State-related cyclical dyskinesias in manic-depressive illness.
Topics: Adult; Bipolar Disorder; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; Male; Mi | 1982 |
Effect of baclofen and haloperidol on gamma-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia.
Topics: Animals; Baclofen; Brain Chemistry; Disease Models, Animal; Dopamine; Drug Interactions; Dyskinesia, | 1982 |
Dopaminergic and GABAergic aspects of tardive dyskinesia [proceedings].
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Receptors, Dopamine; Sulpiride | 1981 |
Evaluation of the role of cortical GABA in the induction of abnormal involuntary movements in rats.
Topics: 4-Aminobutyrate Transaminase; Administration, Topical; Animals; Cerebral Cortex; Dyskinesia, Drug-In | 1981 |
Pharmacologic studies of tardive dyskinesia.
Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Extrapyramidal Tracts; gamma-Aminobutyric Acid; Humans; | 1980 |
Tardive dyskinesia: recognition, management, and prevention.
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Parasympathomimetics | 1980 |
Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Body Weight; Brain; Dyskinesia, Drug-Induced | 1995 |
Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Amino | 1994 |
[What is the connection between Parkinson disease and tardive dyskinesia?].
Topics: Animals; Antipsychotic Agents; Deoxyglucose; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hapl | 1994 |
An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia.
Topics: Animals; Brain Chemistry; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; gamma-Aminobutyri | 1993 |
Dysregulation of striato-nigral GABAergic pathway by chronic haloperidol treatment: the role of dopamine D1 receptor in the substantia nigra pars reticulata on the development of tardive dyskinesia.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Male; Mast | 1993 |
The substantia innominata complex and the peripeduncular nucleus in orofacial dyskinesia: a pharmacological and anatomical study in cats.
Topics: Animals; Behavior, Animal; Cats; Cholera Toxin; Dyskinesia, Drug-Induced; Face; gamma-Aminobutyric A | 1993 |
Choreoathetotic movements: A possible side effect of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Athetosis; Chorea; Cyclohexanecarboxylic Acids; Dyskinesia | 1996 |
Movement disorders associated with the use of gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxylic Acids; Dyskinesia, | 1996 |
Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecar | 1999 |
Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents | 2000 |
Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; gamma-Am | 2000 |
Involvement of GABA neurons in allylnitrile-induced dyskinesia.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Male; Mice; Mice, Inbred | 2000 |
Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Anticonvulsants; Antipsychotic | 2000 |
Animal models of tardive dyskinesia--a review.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Free Radicals; gamm | 2001 |
Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Antineoplastic Agents; Dose-Res | 2001 |
Quetiapine-related tardive dyskinesia.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecarboxy | 2001 |
Decreased pallidal GABA following reverse microdialysis with clozapine, but not haloperidol.
Topics: Animals; Antipsychotic Agents; Calcium; Clozapine; Dose-Response Relationship, Drug; Down-Regulation | 2001 |
Gabapentin-related dyskinesia.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Cyclohexanecarboxylic Acids; Dyskines | 2001 |
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Mode | 2002 |
Improvement in tardive dyskinesia after muscimol therapy.
Topics: Adult; Aged; Antipsychotic Agents; Dopamine; Drug Evaluation; Dyskinesia, Drug-Induced; Extrapyramid | 1979 |
[Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Basal Ganglia Diseases; Bicuculline; Dopamine; Dyskinesia, Drug-Induce | 1979 |
Mass spectrometric identification and selected ion monitoring quantitation of gamma-amino-butyric acid (GABA) in human lumbar cerebrospinal fluid.
Topics: Bipolar Disorder; Chromatography, Gas; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Hu | 1978 |
Dyskinetic effects of intrastriatally injected GABA-transaminase inhibitors.
Topics: 4-Aminobutyrate Transaminase; Animals; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia | 1979 |
[Neurologic adverse manifestations and complications of ambulatory therapy with psychotropic drugs in the late stages].
Topics: Adult; Aged; Antidepressive Agents; Autonomic Nervous System; Basal Ganglia Diseases; Cognition Diso | 1978 |
Evidence for an intrastriatal GABA control on motor activity arising from dopaminergic hyperfuction in the striatum.
Topics: Animals; Apomorphine; Corpus Striatum; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Hydroxydop | 1978 |
The role of GABA in dyskinesias induced by chemical stimulation of the striatum.
Topics: Aminobutyrates; Animals; Bicuculline; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, | 1977 |
Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; | 1992 |
Neuroleptic-induced "painful legs and moving toes" syndrome: successful treatment with clonazepam and baclofen.
Topics: Baclofen; Causalgia; Clonazepam; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; | 1990 |
Anatomically distinct output channels of the caudate nucleus and orofacial dyskinesia: critical role of the subcommissural part of the globus pallidus in oral dyskinesia.
Topics: Animals; Cats; Caudate Nucleus; Disease Models, Animal; Dyskinesia, Drug-Induced; Facial Muscles; ga | 1989 |
Schizophrenia, tardive dyskinesia, and brain GABA.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Female; gamma | 1989 |
Saccadic distractibility in schizophrenic patients with tardive dyskinesia.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Eye Movements; Fixation, Ocular; gamma-Aminobutyric | 1989 |
[Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
Topics: Animals; Catalepsy; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; gamma-Aminobut | 1989 |
[Late dyskinesia: experimental models, paradoxes and deductions].
Topics: Animals; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haplorhini; Humans; Models, Biological; | 1987 |
Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias.
Topics: Animals; Bicuculline; Dyskinesia, Drug-Induced; GABA Antagonists; gamma-Aminobutyric Acid; Injection | 1988 |
Neuroleptic drugs and their action on different neuronal pathways.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Dysk | 1985 |
Experimental tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Brain; Cebus; Corpus Striatum; Disease Models, Animal; Drug Evaluatio | 1985 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
Tardive dyskinesia: nondopaminergic treatment approaches.
Topics: Basal Ganglia; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Lithium; Neurotransmitter | 1985 |
Pathophysiological mechanisms underlying tardive dyskinesia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 1985 |
Clinical and biochemical effects of calcium-hopantenate on neuroleptics-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Male; Middle | 1985 |
Tardive dyskinesia: a role for the endogenous opioid system.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Endorphins; gamm | 1986 |
Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain; Choline O-Acetyltransferase; Dyskinesia, Drug | 1987 |
GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias.
Topics: 4-Aminobutyrate Transaminase; Alkynes; Aminocaproates; Animals; Antipsychotic Agents; Cebus; Dyskine | 1988 |
[The electrophysiological approach to tardive dyskinesias].
Topics: Diagnosis, Differential; Dopamine Agents; Dyskinesia, Drug-Induced; Electromyography; gamma-Aminobut | 1988 |
GABA dysfunction in the pathophysiology of tardive dyskinesia.
Topics: Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Neural Pathways; Neurons; Receptor | 1985 |
New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia.
Topics: Acetylcholine; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma- | 1985 |
3-Mercaptopropionic acid administration into the caudate-putamen of the rat provokes dyskinesia.
Topics: 3-Mercaptopropionic Acid; Animals; Caudate Nucleus; Dyskinesia, Drug-Induced; gamma-Aminobutyric Aci | 1988 |
Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia.
Topics: Aged; Aminocaproates; Carnosine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Mental D | 1987 |
[Tardive dyskinesia--research results and preventive measures].
Topics: Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Receptors, Dopamine; Research | 1987 |
[Vacuous chewing after haloperidol and GABA-linoleamide administration in the rat].
Topics: Animals; Catalepsy; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Haloperidol; Mastication; Psy | 1986 |
Pathophysiology of tardive dyskinesia.
Topics: Animals; Brain; Cebus; Corpus Striatum; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamate | 1985 |
Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.
Topics: Adult; Aged; Aminocaproates; Confusion; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; H | 1985 |
Possible association between tardive dyskinesia and altered carbohydrate metabolism.
Topics: Adult; Blood Glucose; Dyskinesia, Drug-Induced; Fasting; gamma-Aminobutyric Acid; Humans; Middle Age | 1985 |